Northwestern Mutual Wealth Management Co. Has $46,000 Holdings in Bio-Rad Laboratories, Inc. $BIO

Northwestern Mutual Wealth Management Co. lessened its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 30.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 190 shares of the medical research company’s stock after selling 85 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Bio-Rad Laboratories were worth $46,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. Curat Global LLC purchased a new stake in shares of Bio-Rad Laboratories in the 1st quarter valued at about $34,000. Allworth Financial LP raised its holdings in shares of Bio-Rad Laboratories by 260.0% during the 1st quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock valued at $36,000 after buying an additional 104 shares in the last quarter. Headlands Technologies LLC raised its holdings in shares of Bio-Rad Laboratories by 64.1% during the 1st quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock valued at $87,000 after buying an additional 139 shares in the last quarter. Skylands Capital LLC purchased a new position in shares of Bio-Rad Laboratories during the 1st quarter valued at about $122,000. Finally, Mackenzie Financial Corp purchased a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at about $207,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Up 2.0%

BIO opened at $295.27 on Friday. The stock has a market cap of $7.99 billion, a PE ratio of 25.17 and a beta of 0.95. The company has a quick ratio of 3.67, a current ratio of 5.12 and a debt-to-equity ratio of 0.17. The business has a 50 day moving average of $268.80 and a 200-day moving average of $251.78. Bio-Rad Laboratories, Inc. has a 52 week low of $211.43 and a 52 week high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, July 31st. The medical research company reported $2.61 EPS for the quarter, beating analysts’ consensus estimates of $1.93 by $0.68. The company had revenue of $651.60 million during the quarter, compared to analysts’ expectations of $614.82 million. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter last year, the business posted $3.11 EPS. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on BIO. Zacks Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 26th. Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, August 22nd. Wells Fargo & Company raised their price target on Bio-Rad Laboratories from $245.00 to $265.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Finally, Royal Bank Of Canada raised their price target on Bio-Rad Laboratories from $387.00 to $409.00 and gave the stock an “outperform” rating in a research report on Friday, August 1st. Three equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $333.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.